Radiolabelling and cellular binding studies of metformin and indomethacin loaded dual niosome formulations on human colorectal adenocarcinoma cell line

In the current work, film hydration was used for producing indomethacin- and metformin-loaded dual niosomes with a particle size of < 150 nm, a polydispersity index of < 0.5, and a charge of between -30 and -50 mV. [99mTc]Tc was used as a radiolabel for all niosome formulations using stannous chloride as reducing agents. Radioactive thin-layer chromatography (RTLC) was used to evaluate the niosome formulations' radiochemical purity (RP) and stability. Next, the cellular binding of reduced/hydrolyzed (R/H)-[99mTc]NaTcO4 and [99mTc]Tc-labelled niosome formulations was evaluated in human colorectal adenocarcinoma cells. Radiolabelling all niosomes with [99mTc]Tc for 15 min at 500 μg.mL–1 stannous chloride resulted in successful radiolabelling, with an observed RP of over 95%. The cell binding percentages of [99mTc]Tc-labelled niosome formulations in cancer cells were higher than those of R/H- [99mTc]NaTcO4. Finally, the recently developed dual-niosome formulations of metformin and indomethacin labelled with [99mTc]Tc may prove effective for nuclear medicine imaging.